We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+35.64%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$291M
AUM Growth
+$25.4M
Cap. Flow
-$37.9M
Cap. Flow %
-13.02%
Top 10 Hldgs %
53.99%
Holding
96
New
7
Increased
8
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$6.64M
2
AFMD
Affimed
AFMD
+$3.03M
3
STIM icon
Neuronetics
STIM
+$1.8M
4
OTIC
Otonomy, Inc.
OTIC
+$1.15M
5
KURA icon
Kura Oncology
KURA
+$1.03M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$12M
2
WVE icon
Wave Life Sciences
WVE
+$3.94M
3
ASND icon
Ascendis Pharma A/S
ASND
+$3.6M
4
APLS
Apellis Pharmaceuticals
APLS
+$3.57M
5
ARDX icon
Ardelyx
ARDX
+$2.31M

Sector Composition

Rank Sector Weight
1 Healthcare 95.96%
2 Miscellaneous 4.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STXS icon
1
Stereotaxis
STXS
$145M
$72.4M 24.84%
13,680,554
– –
PRQR icon
2
ProQR Therapeutics
PRQR
$323M
$11M 3.79%
1,114,000
+852,479
+326% +$6.64M
ATRC icon
3
AtriCure
ATRC
$2.47B
$10.4M 3.56%
318,729
– –
ARQL
4
DELISTED
Arqule Inc
ARQL
$9.94M 3.41%
497,762
-32,500
-6% -$377K
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$9.87M 3.39%
123,218
– –
LKFT
6
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$9.72M 3.34%
47,000
-5,509
-10% -$1.02M
FATE icon
7
Fate Therapeutics
FATE
$291M
$9.2M 3.16%
470,000
– –
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$9.01M 3.09%
124,806
– –
DXCM icon
9
DexCom
DXCM
$34.3B
$7.95M 2.73%
145,352
– –
IBB icon
10
iShares Biotechnology ETF
IBB
$10.5B
$7.82M 2.68%
64,900
– –
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.7B
$6.56M 2.25%
61,008
-3,500
-5% -$366K
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
$6.47M 2.22%
267,839
-19,909
-7% -$412K
ZGNX
13
DELISTED
Zogenix, Inc.
ZGNX
$5.57M 1.91%
106,749
-36,015
-25% -$1.65M
TVRD
14
Tvardi Therapeutics
TVRD
$24.3M
$5.29M 1.82%
9,126
-1,400
-13% -$982K
AKBA icon
15
Akebia Therapeutics
AKBA
$243M
$4.87M 1.67%
770,538
-57,500
-7% -$273K
LMNX
16
DELISTED
Luminex Corp
LMNX
$4.73M 1.62%
204,091
– –
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.49M 1.54%
98,942
+5,000
+5% +$236K
CYTK icon
18
Cytokinetics
CYTK
$10B
$4.44M 1.53%
418,727
– –
BHVN
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.07M 1.4%
74,700
-20,300
-21% -$1.01M
ASND icon
20
Ascendis Pharma A/S
ASND
$16.3B
$3.91M 1.34%
28,100
-32,380
-54% -$3.6M
YARW
21
Yarrow Bioscience
YARW
$98.8M
$3.7M 1.27%
222
-16
-7% -$267K
XENE icon
22
Xenon Pharmaceuticals
XENE
$5.81B
$3.26M 1.12%
248,854
-81,813
-25% -$861K
AFMD
23
DELISTED
Affimed
AFMD
$3.11M 1.07%
+113,356
New +$3.03M
ACHN
24
DELISTED
Achillion Pharmaceuticals
ACHN
$2.65M 0.91%
438,884
– –
DRNA
25
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.61M 0.89%
118,314
– –
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, DAFNA Capital Management held 96 positions worth $291M, up 9.6% from $266M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

DAFNA Capital Management withdrew a net $37.9M in Q4 2019, closing 15 positions and reducing 27 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Affimed worth $3.11M.

  • DAFNA Capital Management's largest Q4 2019 buy was Affimed: 113,356 shares worth $3.11M.
  • DAFNA Capital Management added most to ProQR Therapeutics in Q4 2019, an estimated $6.64M increase.
  • DAFNA Capital Management's biggest Q4 2019 reduction was Wave Life Sciences, cutting an estimated $3.94M.
  • DAFNA Capital Management fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $12M.
  • DAFNA Capital Management's ten largest holdings make up 54% of its $291M portfolio in Q4 2019.
  • DAFNA Capital Management opened 7 new positions and closed 15 in Q4 2019.
  • DAFNA Capital Management's portfolio value rose 9.6% quarter-over-quarter to $291M.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.